BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

A scan that can detect Alzheimer’s disease before memory loss begins is now available in the UAE for the first time. The amyloid PET scan, recently launched at Cleveland Clinic Abu Dhabi, is a ...

Dementia is a condition that affects memory, thinking, and behavior, and it tends to get worse over time. While there is ...

Andrew Frank and Katherine C. Pearson, QUOI MediaAlzheimer’s disease is an insidious and relentless loss of memory and thinking, accompanied by a gradual ...

.